SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Illustration of Merck's Keytruda (pembro
Drug Development
ASCO: Merck Highlights Keytruda Limitation in NSCLC
While approved in non-small cell lung cancer, Keytruda failed to provide benefit for the TKI-resistant, EGFR-mutant subtype of the disease.
June 6, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Novartis/Courtesy of Adobe Stock, Yingko
Drug Development
ASCO: Novartis’ Kisqali Prevents Breast Cancer Return in Phase III Trial
The Swiss pharma’s CDK4/6 inhibitor reduced risk for recurrence by 25% when added to the standard-of-care endocrine therapy, inviting comparisons to Lilly’s Verzenio.
June 2, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Front of FDA headquarters/Grandbrothers/
Drug Development
FDA Puts Clinical Hold on PepGen’s DM1 Early-Stage Trial
The regulator will provide PepGen with a letter within 30 days explaining why a clinical hold was placed on the company’s Phase 1 study of patients with myotonic dystrophy Type 1.
May 31, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Blue and white Pfizer sign on building/c
Drug Development
Pfizer’s Weekly Injection Reduced Bleeding in Phase III Hemophilia Trial
Marstacimab decreased bleeding rates by 92% in patients with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors.
May 30, 2023
 · 
2 min read
 · 
Kate Goodwin
FDA Headquarters_Grandbrothers/Adobe Stock
FDA
FDA Approves Innoviva’s Bacterial Pneumonia Treatment
The regulator approved Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia. The NDA was filed by Entasis Therapeutics, which Innoviva acquired in 2022.
May 24, 2023
 · 
2 min read
 · 
Kate Goodwin
Smith Collection Gado_Getty Images
Drug Development
Roche Terminates Second Phase II Schizophrenia Trial
The Swiss pharma has canceled a second mid-stage trial for its investigational schizophrenia drug ralmitaront, as the competition shows promise in the space.
May 23, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: A doctor holds a chest x-ray/courtesy of
Drug Development
Phase III Results Prime Dupixent as First Potential Biologic Approval for COPD
Sanofi and Regeneron reported positive results for the anti-inflammatory drug in a chronic obstructive pulmonary disease trial. The companies hope to see approval before a 2024 read-out of a second trial.
May 22, 2023
 · 
2 min read
 · 
Kate Goodwin
Smith Collection Gado_Getty Images
Drug Development
Roche’s MS Drug Hits Phase II Mark, Rivals Remain Under Clinical Holds
Fenebrutinib in a mid-phase trial reduced brain legions in relapsing forms of multiple sclerosis, the company reported. It is the only reversible BTK inhibitor currently in Phase III MS trials.
May 17, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Astellas sign with logo/yu_photo/Adobe S
Business
Astellas, Sony Team on Novel ADC Platform for Oncology
A collaborative research agreement will leverage Sony’s unique polymer, which the companies contend is a stable, effective linker for delivering antibody-drug conjugate payloads to cancer cells.
May 16, 2023
 · 
2 min read
 · 
Kate Goodwin
Bodo Marks/picture alliance via Getty Images
Business
AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova
The company’s second antibody-drug conjugate deal of 2023, with Shanghai-based LaNova Medicines, adds a potential first-in-class GPRC5D-directed ADC for multiple myeloma.
May 15, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Blue sign outside FDA building/JHVEPhoto
Policy
FDA Rejects ImmunityBio’s Bladder Cancer Therapy, Sends Stock Tumbling
The regulator in a Complete Response Letter rejected ImmunityBio’s bladder cancer hopeful due to deficiencies with the company’s third-party contract manufacturer.
May 11, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Scientist holds vial of blood/BlindTurtl
Deals
Sobi Expands Hematology Portfolio with $1.7B Buy of CTI
The acquisition provides the Swedish company with an approved JAK inhibitor for myelofibrosis, a rare bone marrow cancer that disrupts the body’s normal production of blood cells.
May 10, 2023
 · 
2 min read
 · 
Kate Goodwin
Courtesy of Ginkgo Bioworks
Business
Boehringer Ingelheim to Mine Ginkgo’s Molecules in $406M Undruggable Targets Deal
Partnership seeks to identify novel therapeutic molecules to address diseases with high unmet patient needs. It’s the second target discovery company to link with BI in the last month.
May 8, 2023
 · 
2 min read
 · 
Kate Goodwin
AstraZeneca, Pfizer Top 2023 Pharma List for Invention and Innovation
Idea Pharma’s annual index reveals key drivers and metrics for large companies. AstraZeneca and Pfizer remain in the top positions this year for invention and innovation, respectively.
May 5, 2023
 · 
3 min read
 · 
Kate Goodwin
Business
Moderna Reports Modest Income for Q1, Preps for RSV Vaccine Approval and Launch
As the COVID-19 market dries up, Moderna looks to FDA approval of its other vaccines including a 2024 commercial launch of its investigational RSV vaccine for older adults.
May 4, 2023
 · 
3 min read
 · 
Kate Goodwin
Load More